文献速递认知障碍与痴呆

载脂蛋白E ε4与内侧颞叶tau独立于β淀粉样蛋白相关

Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β.
PubMed 文献 · JAMA Neurol · 2020-01-01

该研究基于TRIAD和ADNI两个横断面队列共489名认知正常、轻度认知障碍或阿尔茨海默病痴呆的参与者,发现APOEε4携带者在内嗅皮层和海马区的tau PET摄取增高,且独立于β淀粉样蛋白、性别、年龄和临床状态。结果提示APOEε4增加痴呆风险涉及β淀粉样蛋白和tau聚集双重机制。

要点

  • APOEε4与内嗅皮层和海马tau PET摄取增高独立相关。
  • 该关联独立于β淀粉样蛋白、性别、年龄和临床状态。
  • APOEε4可能成为靶向tau病理的疾病修饰治疗潜在靶点。

核心结论

  • APOEε4与内侧颞叶tau病理独立于β淀粉样蛋白相关,提示其增加痴呆风险涉及β淀粉样蛋白和tau聚集双重机制。

研究设计与样本

  • 研究纳入TRIAD和ADNI两个横断面队列共489名认知正常、轻度认知障碍或阿尔茨海默病痴呆的参与者,均具备淀粉样蛋白PET、tau PET、MRI和APOEε4基因分型数据。

主要发现

  • 在TRIAD队列中,APOEε4与内嗅皮层和海马tau PET摄取增高独立于β淀粉样蛋白、性别、年龄和临床状态相关(β=0.33;95%CI,0.19-0.49;P<.001)。
  • 在ADNI队列中,APOEε4与内嗅皮层和海马tau PET摄取增高独立于β淀粉样蛋白、性别、年龄和临床状态相关(β=0.13;95%CI,0.08-0.19;P<.001)。

关键数值与推荐

  • TRIAD队列:认知正常老年人n=124,轻度认知障碍n=50,阿尔茨海默病n=50;tau PET示踪剂为[18F]MK6240,淀粉样蛋白PET示踪剂为[18F]AZD4694。
  • ADNI队列:认知正常老年人n=157,轻度认知障碍n=83,阿尔茨海默病n=25;tau PET示踪剂为[18F]flortaucipir,淀粉样蛋白PET示踪剂为[18F]florbetapir。
  • 489名参与者平均(SD)年龄70.5(7.1)岁;APOEε4携带者171名(34.9%);男性230名。

临床怎么用

  • 在评估阿尔茨海默病风险时,APOEε4携带状态可提示内侧颞叶tau病理风险增高,独立于淀粉样蛋白负荷。
  • 针对tau病理的疾病修饰治疗试验可考虑将APOEε4作为潜在富集或分层因素。

局限性

  • 本研究为横断面设计,无法推断APOEε4与tau病理之间的因果关系或时间顺序。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Apolipoprotein E ε4 (APOEε4) is the single most important genetic risk factor for Alzheimer disease. While APOEε4 is associated with increased amyloid-β burden, its association with cerebral tau pathology has been controversial. OBJECTIVE: To determine whether APOEε4 is associated with medial temporal tau pathology independently of amyloid-β, sex, clinical status, and age. DESIGN, SETTING, AND PARTICIPANTS: This is a study of 2 cross-sectional cohorts of volunteers who were cognitively normal, had mild cognitive impairment (MCI), or had Alzheimer disease dementia: the Translational Biomarkers in Aging and Dementia (TRIAD) study (data collected between October 2017 and July 2019) and the Alzheimer's Disease Neuroimaging Initiative (ADNI) (collected between November 2015 and June 2019). The first cohort (TRIAD) comprised cognitively normal elderly participants (n = 124), participants with MCI (n = 50), and participants with Alzheimer disease (n = 50) who underwent tau positron emission tomography (PET) with fluorine 18-labeled MK6240 and amyloid-β PET with [18F]AZD4694. The second sample (ADNI) was composed of cognitively normal elderly participants (n = 157), participants with MCI (n = 83), and participants with Alzheimer disease (n = 25) who underwent tau PET with [18F]flortaucipir and amyloid-β PET with [18F]florbetapir. Exclusion criteria were a history of other neurological disorders, stroke, or head trauma. There were 489 eligible participants, selected based on availability of amyloid-PET, tau-PET, magnetic resonance imaging, and genotyping for APOEε4. Forty-five young adults (<30 years) from the TRIAD cohort were not selected for this study. MAIN OUTCOMES AND MEASURES: A main association between APOEε4 and tau-PET standardized uptake value ratio, correcting for age, sex, clinical status, and neocortical amyloid-PET standardized uptake value ratio. RESULTS: The mean (SD) age of the 489 participants was 70.5 (7.1) years; 171 were APOEε4 carriers (34.9%), and 230 of 489 were men. In both cohorts, APOEε4 was associated in increased tau-PET uptake in the entorhinal cortex and hippocampus independently of amyloid-β, sex, age, and clinical status after multiple comparisons correction (TRIAD: β = 0.33; 95% CI, 0.19-0.49; ADNI: β = 0.13; 95% CI, 0.08-0.19; P < .001). CONCLUSIONS AND RELEVANCE: Our results indicate that the elevated risk of developing dementia conferred by APOEε4 genotype involves mechanisms associated with both amyloid-β and tau aggregation. These results contribute to an evolving framework in which APOEε4 has deleterious consequences in Alzheimer disease beyond its link with amyloid-β and suggest APOEε4 as a potential target for future disease-modifying therapeutic trials targeting tau pathology.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Therriault J, Benedet AL, Pascoal TA, et al. Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β. JAMA Neurol. 2020. PMID: 31860000. doi:10.1001/jamaneurol.2019.4421

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。